Splicing misregulation of SCN5A contributes to cardiac-conduction delay and heart arrhythmia in myotonic dystrophy

Nature Communications

Volumn 7, Issue , 2016, Pages

  Freyermuth, Fernande ^a,z   Rau, Frédérique ^b   Kokunai, Yosuke ^c   Linke, Thomas ^d   Sellier, Chantal ^a   Nakamori, Masayuki ^c   Kino, Yoshihiro ^e   Arandel, Ludovic ^b   Jollet, Arnaud ^b   Thibault, Christelle ^a   Philipps, Muriel ^a   Vicaire, Serge ^a   Jost, Bernard ^a   Udd, Bjarne ^f,g,h   Day, John W ⁱ   Duboc, Denis ^j   Wahbi, Karim ^j   Matsumura, Tsuyoshi ^k   Fujimura, Harutoshi ^k   Mochizuki, Hideki ^c   Deryckere, François ^l   Kimura, Takashi ^m   Nukina, Nobuyuki ⁿ   Ishiura, Shoichi ^o   Lacroix, Vincent ^p   Campan Fournier, Amandine ^q   Navratil, Vincent ^r   Chautard, Emilie ^s   Auboeuf, Didier ^s   Horie, Minoru ^t   Imoto, Keiji ^u   Lee, Kuang Yung ^v   Swanson, Maurice S ^w   De Munain, Adolfo Lopez ^x   Inada, Shin ^y   Itoh, Hideki ^t   Nakazawa, Kazuo ^y   Ashihara, Takashi ^t   Wang, Eric ^w   Zimmer, Thomas ^d   Furling, Denis ^b   Takahashi, Masanori P ^c   Charlet Berguerand, Nicolas ^a   more..

^a UNIVERSITÉ DE STRASBOURG   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c OSAKA UNIVERSITY   (Japan)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^e MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^f TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^g UNIVERSITY OF HELSINKI   (Finland)

^h VAASA CENTRAL HOSPITAL   (Finland)

ⁱ STANFORD UNIVERSITY   (United States)

^j UNIVERSITÉ PARIS DESCARTES   (France)

^k TONEYAMA NATIONAL HOSPITAL   (Japan)

^l CNRS   (France)

^m HYOGO COLLEGE OF MEDICINE   (Japan)

ⁿ DOSHISHA UNIVERSITY   (Japan)

^o UNIVERSITY OF TOKYO   (Japan)

^p LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

^q HOSPICES CIVILS DE LYON   (France)

^r UNIVERSITÉ LYON 1   (France)

^s CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^t SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^u NATIONAL INSTITUTE FOR PHYSIOLOGICAL SCIENCES   (Japan)

^v CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^w UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^x HOSPITAL DONOSTIA   (Spain)

^y NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^z MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

SODIUM CHANNEL NAV1.5; RNA BINDING PROTEIN; SCN5A PROTEIN, HUMAN; SODIUM CHANNEL;

CARDIOLOGY; CARDIOVASCULAR SYSTEM; CAUSE OF DEATH; CYTOGENETICS; PROTEIN; RESEARCH WORK; RNA; RODENT;

ADULT; ALTERNATIVE RNA SPLICING; ARTICLE; BINDING SITE; CLINICAL ARTICLE; CONTROLLED STUDY; EXCITABILITY; EXON; FEMALE; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; MALE; MYOTONIC DYSTROPHY; NUCLEOTIDE SEQUENCE; RNA SEQUENCE; AGED; ANIMAL; COMPLICATION; COMPUTER SIMULATION; ELECTROPHYSIOLOGY; GENETICS; HEART MUSCLE CONDUCTION SYSTEM; HEK293 CELL LINE; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE MOTIF; PATHOLOGY; PATHOPHYSIOLOGY; XENOPUS;

MUS;

ADULT; AGED; ALTERNATIVE SPLICING; ANIMALS; ARRHYTHMIAS, CARDIAC; BASE SEQUENCE; BINDING SITES; COMPUTER SIMULATION; ELECTROPHYSIOLOGICAL PHENOMENA; EXONS; FEMALE; HEART CONDUCTION SYSTEM; HEK293 CELLS; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MYOTONIC DYSTROPHY; NAV1.5 VOLTAGE-GATED SODIUM CHANNEL; NUCLEOTIDE MOTIFS; RNA-BINDING PROTEINS; SODIUM CHANNELS; XENOPUS;

EID: 84964334537     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11067     Document Type: Article

References (73)

1. Brook, J. D. et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3 end of a transcript encoding a protein kinase family member. Cell 68, 799-808 (1992).
2. Fu, Y. H. et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 255, 1256-1258 (1992).
3. Mahadevan, M. et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3 untranslated region of the gene. Science 255, 1253-1255 (1992).
4. Liquori, C. L. et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 293, 864-867 (2001).
5. Miller, J. W. et al. Recruitment of human muscleblind proteins to (CUG)n expansions associated with myotonic dystrophy. EMBO J. 19, 4439-4448 (2000).
6. Kanadia, R. N. et al. A muscleblind knockout model for myotonic dystrophy. Science 302, 1978-1980 (2003).
7. Kuyumcu-Martinez, N. M., Wang, G. S. and Cooper, T. A. Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol. Cell 28, 68-78 (2007).
8. Savkur, R. S., Philips, A. V. and Cooper, T. A. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat. Genet. 29, 40-47 (2001).
9. Mankodi, A. et al. Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol. Cell 10, 35-44 (2002).
10. Charlet-B, N. et al. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol. Cell 10, 45-53 (2002).
11. Nakamori, M., Kimura, T., Fujimura, H., Takahashi, M. P. and Sakoda, S. Altered mRNA splicing of dystrophin in type 1 myotonic dystrophy. Muscle Nerve 36, 251-257 (2007).
12. Rau, F. et al. Abnormal splicing switch of DMDs penultimate exon compromises muscle fibre maintenance in myotonic dystrophy. Nat. Commun. 6, 7205 (2015).
13. Fugier, C. et al. Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy. Nat. Med. 17, 720-725 (2011).
14. Kimura, T. et al. Altered mRNA splicing of the skeletal muscle ryanodine receptor and sarcoplasmic/endoplasmic reticulum Ca2+-ATPase in myotonic dystrophy type 1. Hum. Mol. Genet. 14, 2189-2200 (2005).
15. Tang, Z. Z. et al. Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of Ca(V)1.1 calcium channel. Hum. Mol. Genet. 21, 1312-1324 (2012).
16. Wheeler, T. M., Lueck, J. D., Swanson, M. S., Dirksen, R. T. and Thornton, C. A. Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J. Clin. Invest. 117, 3952-3957 (2007).
17. Groh, W. J. et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N. Engl. J. Med. 358, 2688-2697 (2008).
18. Lazarus, A. et al. Long-term follow-up of arrhythmias in patients with myotonic dystrophy treated by pacing: a multicenter diagnostic pacemaker study. J. Am. Coll. Cardiol. 40, 1645-1652 (2002).
19. Chen, Q. et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 392, 293-296 (1998).
20. Tan, H. L. et al. A sodium-channel mutation causes isolated cardiac conduction disease. Nature 409, 1043-1047 (2001).
21. Schott, J. J. et al. Cardiac conduction defects associate with mutations in SCN5A. Nat. Genet. 23, 20-21 (1999).
22. Anders, S., Reyes, A. and Huber, W. Detecting differential usage of exons from RNA-seq data. Genome Res. 22, 2008-2017 (2012).
23. Katz, Y., Wang, E. T., Airoldi, E. M. and Burge, C. B. Analysis and design of RNA sequencing experiments for identifying isoform regulation. Nat. Methods 7, 1009-1015 (2010).
24. Philips, A. V., Timchenko, L. T. and Cooper, T. A. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science 280, 737-741 (1998).
25. Nakamori, M. et al. Splicing biomarkers of disease severity in myotonic dystrophy. Ann. Neurol. 74, 862-872 (2013).
26. Kalsotra, A. et al. A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proc. Natl Acad. Sci. USA 105, 20333-20338 (2008).
27. Banks, A. S. et al. Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of Langerhans. J. Clin. Invest. 115, 2462-2471 (2005).
28. Wani, M. A. et al. Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2- microglobulin gene. Proc. Natl Acad. Sci. USA 103, 5084-5089 (2006).
29. Yuan, Y. et al. Muscleblind-like 1 interacts with RNA hairpins in splicing target and pathogenic RNAs. Nucleic Acids Res. 35, 5474-5486 (2007).
30. Kino, Y. et al. Muscleblind protein, MBNL1/EXP, binds specifically to CHHG repeats. Hum. Mol. Genet. 13, 495-507 (2004).
31. Goers, E. S., Purcell, J., Voelker, R. B., Gates, D. P. and Berglund, J. A. MBNL1 binds GC motifs embedded in pyrimidines to regulate alternative splicing. Nucleic Acids Res. 38, 2467-2484 (2010).
32. Teplova, M. and Patel, D. J. Structural insights into RNA recognition by the alternative-splicing regulator muscleblind-like MBNL1. Nat. Struct. Mol. Biol. 15, 1343-1351 (2008).
33. Marquis, J. et al. CUG-BP1/CELF1 requires UGU-rich sequences for high-affinity binding. Biochem. J. 400, 291-301 (2006).
34. Teplova, M., Song, J., Gaw, H. Y., Teplov, A. and Patel, D. J. Structural insights into RNA recognition by the alternate-splicing regulator CUG-binding protein 1. Structure 18, 1364-1377 (2010).
35. Wang, E. T. et al. Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins. Cell 150, 710-724 (2012).
36. Goodwin, M. et al. MBNL sequestration by toxic RNAs and RNA misprocessing in the myotonic dystrophy brain. Cell Rep. 12, 1159-1168 (2015).
37. Lin, X. et al. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum. Mol. Genet. 15, 2087-2097 (2006).
38. Kanadia, R. et al. Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc. Natl Acad. Sci. USA 103, 11748-11753 (2006).
39. Murphy, L. L. et al. Developmentally regulated SCN5A splice variant potentiates dysfunction of a novel mutation associated with severe fetal arrhythmia. Heart Rhythm. 9, 590-597 (2012).
40. Walzik, S., Schroeter, A., Benndorf, K. and Zimmer, T. Alternative splicing of the cardiac sodium channel creates multiple variants of mutant T1620K channels. PLoS ONE 6, e19188 (2011).
41. Onkal, R. et al. Alternative splicing of Nav1.5: an electrophysiological comparison of neonatal and adult isoforms and critical involvement of a lysine residue. J. Cell. Physiol. 216, 716-726 (2008).
42. Wahbi, K. et al. Brugada syndrome and abnormal splicing of SCN5A in myotonic dystrophy type 1. Arch. Cardiovasc. Dis. 106, 635-643 (2013).
43. Lee, K. Y. et al. Compound loss of muscleblind-like function in myotonic dystrophy. EMBO Mol. Med. 5, 1887-1900 (2013).
44. Dixon, D. M. et al. Loss of muscleblind-like 1 results in cardiac pathology and persistence of fetal splice isoforms. Sci. Rep. 5, 9042 (2015).
45. Leoni, A. L. et al. Variable Na(v)1.5 protein expression from the wild-type allele correlates with the penetrance of cardiac conduction disease in the Scn5a(+/-) mouse model. PLoS ONE 5, e9298 (2010).
46. Royer, A. et al. Mouse model of SCN5A-linked hereditary Lenegres disease: age-related conduction slowing and myocardial fibrosis. Circulation 111, 1738-1746 (2005).
47. van Veen, T. A. et al. Impaired impulse propagation in Scn5a-knockout mice: combined contribution of excitability, connexin expression, and tissue architecture in relation to aging. Circulation 112, 1927-1935 (2005).
48. OHara, T., Virag, L., Varro, A. and Rudy, Y. Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation. PLoS Comput. Biol. 7, e1002061 (2011).
49. Tsuji-Wakisaka, K. et al. Identification and functional characterization of KCNQ1 mutations around the exon 7-intron 7 junction affecting the splicing process. Biochim. Biophys. Acta 1812, 1452-1459 (2011).
50. Inada, S., Hancox, J. C., Zhang, H. and Boyett, M. R. One-dimensional mathematical model of the atrioventricular node including atrio-nodal, nodal, and nodal-his cells. Biophys. J. 97, 2117-2127 (2009).
51. Probst, V. et al. Progressive cardiac conduction defect is the prevailing phenotype in carriers of a Brugada syndrome SCN5A mutation. J. Cardiovasc. Electrophysiol. 17, 270-275 (2006).
52. Zhang, Z. S., Tranquillo, J., Neplioueva, V., Bursac, N. and Grant, A. O. Sodium channel kinetic changes that produce Brugada syndrome or progressive cardiac conduction system disease. Am. J. Physiol. Heart Circ. Physiol. 292, H399-H407 (2007).
53. Wang, D. W., Viswanathan, P. C., Balser, J. R., George, Jr A. L. and Benson, D. W. Clinical, genetic, and biophysical characterization of SCN5A mutations associated with atrioventricular conduction block. Circulation 105, 341-346 (2002).
54. Rudnik-Schoneborn, S. et al. Brugada-like cardiac disease in myotonic dystrophy type 2: report of two unrelated patients. Eur. J. Neurol. 18, 191-194 (2011).
55. Pambrun, T. et al. Unmasked Brugada pattern by Ajmaline challenge in patients with myotonic dystrophy type 1. Ann. Noninvasive Electrocardiol. 20, 28-36 (2015).
56. Maury, P. et al. Prevalence of type 1 Brugada-ECG pattern following administration of Class 1C drugs in patients with type 1 myotonic dystrophy: myotonic dystrophy as a part of the Brugada syndrome. Heart Rhythm. 11, 1721-1727 (2014).
57. Algalarrondo, V. et al. Abnormal sodium current properties contribute to cardiac electrical and contractile dysfunction in a mouse model of myotonic dystrophy type 1. Neuromuscul. Disord. 25, 308-320 (2014).
58. Yadava, R. S. et al. RNA toxicity in myotonic muscular dystrophy induces NKX2-5 expression. Nat. Genet. 40, 61-68 (2008).
59. Koshelev, M., Sarma, S., Price, R. E., Wehrens, X. H. and Cooper, T. A. Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1. Hum. Mol. Genet. 19, 1066-1075 (2010).
60. Kalsotra, A. et al. The Mef2 transcription network is disrupted in myotonic dystrophy heart tissue, dramatically altering miRNA and mRNA expression. Cell Rep. 6, 336-345 (2014).
61. Rau, F. et al. Misregulation of miR-1 processing is associated with heart defects in myotonic dystrophy. Nat. Struct. Mol. Biol. 18, 840-845 (2011).
62. Gorog, D. A., Russell, G., Casian, A. and Peters, N. S. A cautionary tale: the risks of flecainide treatment for myotonic dystrophy. J. Clin. Neuromuscul. Dis. 7, 25-28 (2005).
63. Otten, R. F. et al. Arrhythmia exacerbation after sodium channel blockade in myotonic dystrophy type 1. Muscle Nerve 40, 901-902 (2009).
64. Groh, W. J., Lowe, M. R., Simmons, Z., Bhakta, D. and Pascuzzi, R. M. Familial clustering of muscular and cardiac involvement in myotonic dystrophy type 1. Muscle Nerve 31, 719-724 (2005).
65. Pambrun, T. et al. Myotonic dystrophy type 1 mimics and exacerbates Brugada phenotype induced by Nav1.5 sodium channel loss-of-function mutation. Heart Rhythm. 11, 1393-1400 (2014).
66. Childs-Disney, J. L. et al. Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules. Nat. Commun. 4, 2044 (2013).
67. Wheeler, T. M. et al. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488, 111-115 (2012).
68. Nakamori, M. et al. Aberrantly spliced alpha-dystrobrevin alters alphasyntrophin binding in myotonic dystrophy type 1. Neurology 70, 677-685 (2008).
69. Schoser, B. G. et al. Sudden cardiac death in myotonic dystrophy type 2. Neurology 63, 2402-2404 (2004).
70. Udd, B., Krahe, R., Wallgren-Pettersson, C., Falck, B. and Kalimo, H. Proximal myotonic dystrophy-a family with autosomal dominant muscular dystrophy, cataracts, hearing loss and hypogonadism: heterogeneity of proximal myotonic syndromes? Neuromuscul. Disord. 7, 217-228 (1997).
71. Kim, D. et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14, R36 (2013).
72. Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat. Biotechnol. 28, 511-515 (2010).
73. Goyenvalle, A. et al. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 306, 1796-1799 (2004).